SEC Form 6-K filed by PainReform Ltd.

Washington, D.C. 20549

 

 

Report of Foreign Private Issuer

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the month of November 2024

 

Commission File Number: 001-39481

 

(Translation of registrant’s name into English)

 

65 Yigal Alon St., Tel Aviv 6744316

Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This first three paragraphs of the press release attached as Exhibit 99.1 to this Report on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the Company’s Registration Statements on Form F-3 (Registration No. 333-282264, 333-254982, 333-276485 and 333-277594)., to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

On November 20, 2024 PainReform Ltd. issued a press release entitled “PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial”. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

EXHIBIT INDEX

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

---